Instruments

Name Stock exchange Average volume Price Type
CHRISTIAN DIOR SE CHDRY

OTC Markets +2 Other

51 192 USD Stock Christian Dior SE Stock
CHRISTIAN DIOR SE DIO0

Deutsche Boerse AG

- 176 EUR Stock Christian Dior SE
CHRISTIAN DIOR SE DIO0

Börse Stuttgart

- 177 EUR Stock Christian Dior SE
CHRISTIAN DIOR SE CDI

Euronext Paris +7 Other

3,213 718 EUR Stock Christian Dior SE Stock
CHRISTIAN DIOR SE DIO

Deutsche Boerse AG

- 714 EUR Stock Christian Dior SE
CHRISTIAN DIOR SE 0NPL

London S.E.

0 717.5 EUR Stock Christian Dior SE
CHRISTIAN DIOR SE DIO

Börse Stuttgart

- 716.5 EUR Stock Christian Dior SE
CHRISTIAN DIOR SE DIO

BOERSE MUENCHEN

4 713 EUR Stock Christian Dior SE
CHRISTIAN DIOR SE CDI

Wiener Boerse

- 738.5 EUR Stock Christian Dior SE
CHRISTIAN DIOR SE CHDRF

OTC Markets

29 789 USD Stock Christian Dior SE
CHRISTIAN DIOR SE DIO

Frankfurt

6 719 EUR Stock Christian Dior SE
CHRISTIAN HANSEN CHYHY

OTC Markets

18,617 19.58 USD Stock Christian Hansen Stock
CHRISTIAN HANSEN HOLDING A/S (HL6) - ELA/20240621

Euronext Amsterdam

- 556.8 DKK Future CHRISTIAN HANSEN HOLDING A/S (HL6) - ELA/20240621 Future
CHRISTIAN HANSEN HOLDING A/S (HL6) - ELA/20240315

Euronext Amsterdam

- 551.9 DKK Future CHRISTIAN HANSEN HOLDING A/S (HL6) - ELA/20240315 Future
CHRISTIAN HANSEN HOLDING A/S (HL6) - ELA/C1

Euronext Amsterdam

- 549.6 DKK Future CHRISTIAN HANSEN HOLDING A/S (HL6) - ELA/C1 Future
CHRISTIAN HANSEN HOLDING A/S (HL6) - ELA/C2

Euronext Amsterdam

- 549.6 DKK Future CHRISTIAN HANSEN HOLDING A/S (HL6) - ELA/C2 Future
CHRISTIAN HANSEN HOLDING A/S (HL6) - ELA/C6

Euronext Amsterdam

- 542.5 DKK Future CHRISTIAN HANSEN HOLDING A/S (HL6) - ELA/C6 Future
CHRISTIAN HANSEN HOLDING A/S (HL6) - ELA/20240419

Euronext Amsterdam

- 553.6 DKK Future CHRISTIAN HANSEN HOLDING A/S (HL6) - ELA/20240419 Future
CHRISTIAN HANSEN HOLDING A/S (HL6) - ELA/C3

Euronext Amsterdam

- 549.6 DKK Future CHRISTIAN HANSEN HOLDING A/S (HL6) - ELA/C3 Future

News (73)

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results AQ
Bayer and Evotec collaborate to advance precision cardiology EQ
Bayer Pharmaceuticals streamlines Leadership Team for next phase of growth AQ
Bayer - Positive topline results from Phase III long-term study OASIS 3 support submissions for marketing authorization for Bayer's elinzanetant AQ
Bayer plans to apply for approval of drug to treat menopausal symptoms DP
CRISPR Therapeutics Proposes New Appointment to the Board of Directors AQ
Bayer AG - BlueRock Therapeutics phase I clinical trial for Parkinson's disease continues to show positive trends at 18 months AQ
Bayer : BlueRock Therapeutics phase I clinical trial for Parkinson’s disease continues to show positive trends at 18 months PU
Transcript : Bayer Aktiengesellschaft - Analyst/Investor Day
Transcript : Bayer Aktiengesellschaft, 2023 Earnings Call, Mar 05, 2024
Bayer initiates Phase II study with first-in-class anti-alpha2 antiplasmin antibody in patients with deep vein thrombosis AQ
Bayer AG - First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure AQ
Vividion Therapeutics starts Phase I clinical trial in advanced solid and hematologic tumors with oral STAT3 inhibitor AQ
Transcript : Bayer Aktiengesellschaft Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 11:15 AM
Bayer starts Phase II study NIRVANA to evaluate elinzanetant in women with sleep disturbances associated with menopause AQ
Bayer's elinzanetant meets all primary and key secondary endpoints in pivotal OASIS 1 and 2 Phase III studies AQ
Transcript : Bayer Aktiengesellschaft - Special Call
Bayer - OCEANIC-AF study stopped early due to lack of efficacy AQ
Bayer Stops Late-Stage Study for Stroke Prevention Due to Lack of Efficacy DJ
Bayer : aflibercept 8 mg recommended for approval in EU PU
Bayer - New asundexian Phase III study to include patients with atrial fibrillation ineligible for oral anticoagulant treatment AQ
Bayer : New asundexian Phase III study to include patients with atrial fibrillation ineligible for oral anticoagulant treatment PU
Bayer : Vividion Therapeutics starts Phase I clinical trial in advanced solid tumors with KEAP1 activator PU
Bayer : BlueRock’s Phase I study with bemdaneprocel in patients with Parkinson’s disease meets primary endpoint PU
Bayer says Parkinson's stem cell therapy improves symptoms in initial trial RE
Transcript : Bayer Aktiengesellschaft, Q2 2023 Earnings Call, Aug 08, 2023
Bayer - BlueRock's neuronal stem cell therapy for Parkinson's disease is first to show positive results in Phase I clinical study AQ
Bayer's new pharmaceutical R&D strategy to accelerate breakthrough innovations AQ
Transcript : Bayer Aktiengesellschaft - Special Call
Bayer : receives U.S. FDA Fast Track Designation for asundexian atrial fibrillation program PU
Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology BU
Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology BU
Bayer : submits aflibercept 8 mg for marketing authorization in Japan PU
Bayer : submits aflibercept 8 mg for regulatory approval in two major retinal eye diseases in the EU PU
Bayer progressing well with transformation of pharma business and raises peak sales potential of key growth drivers to over twelve billion euros AQ
Bayer Raises Combined Peak Sales Forecast for Pharma Portfolio DJ
Finerenone receives positive CHMP opinion for EU-label extension for broad range of patients with chronic kidney disease and type 2 diabetes AQ
Bayer : Finerenone receives positive CHMP opinion for EU-label extension for broad range of patients with chronic kidney disease and type 2 diabetes PU
Bayer : receives positive CHMP opinion for Eylea™ in the EU for treatment of preterm infants with retinopathy of prematurity PU
Bayer AG - Detailed data from pivotal studies with aflibercept 8 mg demonstrate sustained improvements in visual acuity and anatomic measures with large majority of patients maintaining treatment intervals of 16 AQ
Bayer : Detailed data from pivotal studies with aflibercept 8 mg demonstrate sustained improvements in visual acuity and anatomic measures with large majority of patients maintaining treatment intervals of 16 PU
Bayer expands development program for elinzanetant with Phase III study in breast cancer patients with vasomotor symptoms caused by endocrine therapy AQ
Bayer AG - Aflibercept 8 mg first to achieve extended injection intervals of 16 weeks in up to 89% of patients AQ
Bayer : opens new Research & Innovation Center in Boston-Cambridge demonstrating its commitment to precision oncology PU
Bayer : delivers on medical innovation fueling transformation of pharma business PU
12NextSee all

Companies (10)

CHRISTIAN DIOR SE 139 B $
Logo Christian Dior SE

Christian Dior SE is a holding company organized around 6 areas of activity: - sale of fashion products and leather goods (48.9% of net sales): primarily Louis Vuitton, Fendi, Céline, Loewe, Givenchy, Kenzo, Thomas Pink, Berluti, Pucci and Loro Piana bra ...

LVMH 407 B $
Logo LVMH

LVMH Moët Hennessy Louis Vuitton SE is the world leader in luxury products. Net sales break down by family of products as follows: - fashion and leather items (48.9%): brands such as Louis Vuitton, Kenzo, Celine, Fendi, Marc Jacobs, Givenchy, etc.; - wa ...

IEXALT, INC. 222 $
Logo iExalt, Inc.

iExalt Inc. provides products, services and technology solutions to Christian families, businesses, schools, communities and organizations. The Company markets filtered Internet service; publishes Christian electronic books and reference materials, a Chri ...

BOLIVAR MINING - $
Logo BOLIVAR MINING

Bolivar Mining Corp., formerly Denim Apparel Group Inc., used to operate as a media communications and product company for the Christian marketplace. The Company's primary media property was Christian Times Today, a monthly newspaper distributed by and to ...

DIERIG HOLDING AG 45 M $
Logo Dierig Holding AG

Dierig Holding AG is a Germany-based holding company. The Company is engaged in producing bed linen, trade internationally in raw and finished fabrics, technical textiles and offer contract textiles for hotels, hospitals and care facilities on an order-re ...

SALEM MEDIA GROUP, INC. 9 M $
Logo Salem Media Group, Inc.

Salem Media Group, Inc. is a domestic multimedia company specializing in Christian and conservative content, with media properties comprising radio broadcasting, digital media, and publishing. Its segments include Broadcast, Digital Media and Publishing. ...

SPARK NETWORKS SE 26 $
Logo Spark Networks SE

Spark Networks SE is a Germany-based Company, which is a global dating company with a portfolio of brands designed for singles seeking serious relationships. The Company operates online dating sites and mobile applications. It focuses on catering to the 4 ...

THE REALREAL, INC. 431 M $
Logo The RealReal, Inc.

The RealReal, Inc. provides an online marketplace for authenticated, consigned luxury goods. The Company provides a platform for consumers to buy and sell their luxury items. The Company offers products across multiple categories, including women's fashio ...

BERNER INDUSTRIER AB 60 M $
Logo Berner Industrier AB

Christian Berner Tech Trade AB is a Sweden-based technical sales company. It operates as a supplier of technical equipment, components and materials. The Company is active in two business areas: Material Technology, comprising sales of various kinds of ma ...

OLYMPIC CARDS LIMITED 683 554 $
Logo Olympic Cards Limited

Olympic Cards Limited is mainly involved in manufacturing and trading of wedding invitation cards, greeting cards, visiting cards, office envelopes, cloth-lined covers, student notebooks, account books, files and others. The Company is also involved in th ...


Insiders


Picture Christian Rommel
Christian Rommel

Christian Rommel is currently a Director at Asklepios BioPharmaceutical, Inc., Vividion Therapeutics, Inc., CRISPR Therapeutics AG, and Bayer AG.
He previously worked as a Senior Scientist at Regeneron Pharmaceuticals, Inc., SVP and Head of Oncology Research & Early Development at F.
Hoffmann-La Roche Ltd., Chief Scientific Officer at Intellikine LLC, and Head of Target Research at Merck Serono Ltd.
He holds a doctorate degree from the Max-Planck-Institute for Molecular Genetics and an undergraduate degree from the University of Greifswald.







Picture Rommel B. Narvaez
Rommel B. Narvaez

Rommel B.
Narvaez
worked as SVP, Head-Marketing & Brand Management Sector at Philippine National Bank from 2019 to 2020.
Prior to that, he worked as SVP & Head-Corporate Communications at East West Banking Corp.
Mr. Narvaez completed his undergraduate degree at De La Salle University.


Picture Rommel C. Saber
Rommel C. Saber

Rommel C.
Saber
served as the President-Europe, Africa & Middle East at Expeditors International of Washington, Inc. from 1990 to 2015.

No results for this search